GlassScriptPhysician profile
Jae Hee Choe
NPI 1144849910
$3,165.05
in general payments reported to CMS, 2019-2025
21 companies · $806 in 2025
The $806 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $686 · 2024: $1,674 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,165.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $502.92 | 2023-2024 | Vemlidy, Epclusa |
| Amgen INC. | $370.54 | 2024-2025 | Evenity, Repatha, Otezla |
| Ibsa Pharma INC. | $309.90 | 2023-2025 | Licart, Tirosint, Tirosint |
| Bayer Healthcare Pharmaceuticals INC. | $259.63 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $217.39 | 2024 | Breztri, Farxiga |
| Abbvie INC. | $217.27 | 2023-2025 | Qulipta, Ubrelvy |
| Ironwood Pharmaceuticals, INC | $173.57 | 2024 | |
| Boston Scientific Corporation | $157.97 | 2024 | |
| Glaxosmithkline, LLC. | $154.74 | 2023-2025 | Trelegy Ellipta, Bexsero |
| Novo Nordisk INC | $151.34 | 2024-2025 | Ozempic, Wegovy |
| Phathom Pharmaceuticals, INC. | $149.99 | 2025 | Voquezna |
| Exact Sciences Corporation | $98.89 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ardelyx, INC. | $90.59 | 2024-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $83.27 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.53 | 2023-2024 | Jardiance |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $40.33 | 2024-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Lilly USA, LLC | $31.21 | 2024 | Mounjaro, Zepbound |
| Sanofi Pasteur INC. | $27.99 | 2023 | |
| Pfizer INC. | $22.51 | 2023 | |
| Agios Pharmaceuticals, INC. | $22.07 | 2025 | Pyrukynd |
| Xeris Pharmaceuticals, INC. | $18.40 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jae Choe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.